Reference SummaryEstensen RD, Carcinogenesis 2004 Feb;25(2):197-201
Title |
Effect of chemopreventive agents on separate stages of progression of benzo[alpha]pyrene induced lung tumors in A/J mice. |
Authors |
Estensen RD; Jordan MM; Wiedmann TS; Galbraith AR; Steele VE; Wattenberg LW |
Journal |
Carcinogenesis |
Volume |
25 |
Issue |
2 |
Year |
2004 |
Pages |
197-201 |
Abstract |
The effects of aerosol budesonide and dietary myo-inositol on progression of benzo[alpha]pyrene (B[alpha]P) induced carcinogenesis were studied in A/J mouse lung. First, we determined when to intervene in the carcinogenesis process by exposing several animals to B[alpha]P at 100 and 150 mg/kg of body wt. Groups of these animals were necropsied from 1 to 36 weeks post-carcinogen. The presence of different categories of lung tumors was noted over the 36 week time period. Hyperplasia first appeared approximately 6 weeks post-carcinogen followed by adenoma at 9 weeks, then by carcinoma at 26 weeks. From this temporal sequence we determined we could test for effects of preventive agents on progression to hyperplasia by intervening at 3 weeks, for effects on progression to adenoma by intervening at 6 weeks and for effects on progression to carcinoma by intervention at 12 weeks. Intervention at 3 weeks post-carcinogen with aerosolized budesonide delayed both hyperplasia and adenoma formation. Once hyperplasia appeared in budesonide treated animals, however, it increased at the same rate as in control animals, indicating a delay in progression. Progression from adenoma to carcinoma was reduced when budesonide was given 12 weeks post-carcinogen. Dietary myo-inositol failed to suppress progression from adenoma to carcinoma when started 12 weeks post-carcinogen. In summary, budesonide is a chemopreventive agent that has inhibitory effects on B[alpha]P induced carcinogenesis of the lung in A/J mice at all stages of progression from hyperplasia formation to cancer. |
Links |
J:88491 – MGI References 14578161 – National Library of Medicine/PubMed |
| Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
|---|---|---|---|---|---|
| A/J | Lung adenoma |
|
Lung |
0 - observed |
|
| A/J | Lung adenoma |
|
Lung |
0 - observed |
|
| A/J | Lung adenoma |
|
Lung |
observed |
|
| A/J | Lung adenoma |
|
Lung |
observed |
|
| A/J | Lung carcinoma |
|
Lung |
0 - observed |
|
| A/J | Lung carcinoma |
|
Lung |
observed |
|
| A/J | Lung carcinoma |
|
Lung |
observed |
|
| A/J | Lung carcinoma |
|
Lung |
observed |
|
| A/J | Lung hyperplasia |
|
Lung |
0 - observed |
|
| A/J | Lung hyperplasia |
|
Lung |
0 - observed |
|
| A/J | Lung hyperplasia |
|
Lung |
observed |
|
| A/J | Lung hyperplasia |
|
Lung |
observed |
|
| A/J | Lung tumor |
|
Lung |
observed |
|
| A/J | Lung tumor |
|
Lung |
observed |
|
| A/J | Lung tumor | Lung |
observed |
||
| A/J | Lung tumor |
|
Lung |
observed |